Radiopharmaceutical Products

Award

Buyers

Value

£453,369

Suppliers

Classifications

  • Pharmaceutical products

Tags

  • award

Submission Deadline

1 year ago

Published

7 months ago

Description

Provision of Radiopharmaceutical Product

Additional information: 
NOECPC framework Provision of Radiopharmaceuticals and associated consumables OJEU Reference 2023/S000-017484 and NOE CPC Project Reference NOE.0585

Documents

Premium

Bypass the hassle of outdated portals. Get all the information you need right here, right now.

  • Contract Agreement

    The official contract terms, conditions, and scopes of work.

    Download

  • Award Notice

    Details on the tender award and selected suppliers.

    Download

Similar Contracts

Open

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: [email protected]

NHS England

NHS England

Published 1 month ago
Open

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/><br/>CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines – Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/><br/>CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines – Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

NHS England

NHS England

Published 1 month ago
Open

IMP Manufacture, Labelling and Packaging DPS

The London School of Hygiene and Tropical Medicine (LSHTM) is implementing a Dynamic Purchasing System (DPS) for the procurement of services related to the provision of investigational medicinal products (IMPs) for clinical trials. The DPS is intended to be a long term, 10 year, system to support the work of the CTU for both large and small trials.

London School of Hygiene & Tropical Medicine

London School of Hygiene & Tropical Medicine

Published 7 months ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Organisation

United Lincolnshire Hospitals NHS Trust

Body governed by public law

Kirsty Jobson

[email protected]

01522 307820

Timeline complete

Publish
Bid
Evaluate
Award
Complete